The following information is exclusively reserved for physicians practicing in Austria, the Netherlands, Spain, and Switzerland where the Zio™ monitor ECG monitoring service is currently authorised and made available for use in accordance with local regulatory requirements.

Learn more
Search

Completely Transforming Cardiac Monitoring

The end-to-end iRhythm monitoring service features our state-of-the art monitors, our advanced AI Zio™ ECG Utilization Service (ZEUS) System which is CE-marked and FDA cleared and highly trained Qualified ECG Specialists (QES), offering your practice a comprehensive approach to cardiac monitoring.1-4

Patient with doctor
Two hikers holding hands

Step-by-step simplicity

Physicians prescribe the iRhythm monitoring service, and the Zio ECG ambulatory monitor is applied to the patient in clinic.

Patient wears the monitor and then mails it back to iRhythm.

iRhythm analyzes the data, leveraging a proprietary, deep learned AI algorithm (ZEUS) and a team of highly trained QES's who will curate the data and provide a final end-of-wear report.

Physicians then receive the high-quality, clinically actionable end of wear report to support with their diagnosis.

The impact of accuracy

The end-to-end iRhythm monitoring service creates a better experience for you and your patients and helps you achieve your department goals.5-12

Zio long-term continuous monitoring (LTCM) improved clinical outcomes

  • 2x more likely to result in specified arrhythmia diagnoses compared to Holter monitoring services12,18-19
  • 2.6x greater detection of atrial fibrillation vs. usual care8,14-16

LTCM improved clinical accuracy

  • Zio LTCM service allowed for longer continuous monitoring resulting in an improvement in clinical accuracy and a meaningful change in clinical management8-9,11,14,17
  • Lowest likelihood of retest among continuous cardiac monitoring services5,12,23

Higher patient satisfaction

  • 81% of patients preferred wearing a Zio LTCM monitor over a Holter7,12,13
  • 91% of patients wearing Zio monitor report it is easy to use and 90% would wear again12,18,19

Monitors that deliver the power of precision

Zio ECG monitors are specifically designed to fit patients’ daily lives, leading to astounding patient compliance.10,12,18,20-21 They offer high-quality, accurate data you can trust and help lead to the right diagnosis the first time.10,20,22

Zio monitor

Zio™ monitor

Long-term continuous monitoring

The thinnest and lightest LTCM monitor20 delivers an improved patient experience that results in 99% patient compliance with prescribed wear times.10,12,21

Learn more

Everything physicians need, all in one place

End to end, the iRhythm monitoring service is equipped with data management solutions and advanced AI that help you focus

on what matters most — your patients.

A sample of the ZioSuite

Zio™ monitor

A single‑use wearable ECG monitor prescribed by a clinician.
Discover Zio™ monitor

ZioSuite™

A secure platform that enables clinicians to access & interpret patient reports, manage patients, and more​.
See the clinician portal

EHR Integration

Simplifies data collection and entry, enhances interdisciplinary access, and boosts workflow efficiency.
Simplify your workflow

Zio™ Reports

Equips clinicians with data analysis of the full wear time, verified by Qualified ECG Specialists (QES).
See the reports

Continue the conversation

The Zio™ service helps you detect arrhythmias earlier, reduce administrative burden, and enhance patient experience — all through a single, streamlined platform.

 

Connect with an iRhythm specialist today to discover how the Zio™ Service can fit into your workflow.

Continue the conversation
Man with child on his shoulders
  1. Data on file. iRhythm Technologies, 2020. 
  2. Hannun et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25:65-69.https://doi.org/10.1038/s41591-018-0268-3 
  3. Deep learned algorithm is only available in the United States, European Union, Switzerland, United Kingdom, and Japan.  
  4. FDA 510K clearance, CE mark, UKCA mark, and PMDA-approval. 
  5. Reynolds et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024;269:25–34. https://doi.org/10.1016/j.ahj.2023.12.002 
  6. Diagnostic yield was assessed based upon the evaluation of specified arrhythmias, which refer to an arrhythmia encounter diagnosis as per Hierarchical Condition Categories (HCC) 96. 
  7. Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file.  
  8. Zio LTCM service refers to Zio XT and Zio monitor service. 
  9. Contraindications: Do not use the Zio monitor for critical care patients or for patients with symptomatic episodes where instance variations in cardiac performance could result in immediate danger to the patients or when real-time or in-patient monitoring should be prescribed. (Refer to the Zio monitor Instructions for Use for the full list of contraindications.) 
  10. Zio service provides continuous, uninterrupted recording and a comprehensive end-of-wear report. 
  11. Zio monitor and ZEUS are CE-marked. 
  12. Based on US data. 
  13. Barrett et al. Comparison of 24-hour Holter Monitoring with 14-day Novel Adhesive Patch Electrocardiographic Monitoring. The American Journal of Medicine. 2014;127(1):95.e11-95.e17. doi:https://doi.org/10.1016/j.amjmed.2013.10.003 
  14. Based on previous generation Zio XT device data. Zio monitor utilizes the same operating principles and ECG algorithm. Additional data on file. 
  15. Steinhubl et al. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation. JAMA. 2018;320(2):146. doi:https://doi.org/10.1001/jama.2018.8102 
  16. This is a US study in which US participants received their Zio device by postal mail, and self-applied the patch.  Follow-up events, including the hospitalizations mentioned, were derived from analyzing healthcare/medical claims database for the study participants. 
  17. Rosenberg et al. Use of a noninvasive continuous monitoring device in the management of Atrial Fibrillation: A pilot study. Pacing and Clinical Electrophysiology. 2012;36(3):328-333. doi:10.1111/pace.12053 
  18. Battisti et al. Abstract 4141717: Feasibility of point-of-wear patient satisfaction surveys to validate patient-centered product enhancements: results from over 300,000 patients for long-term ambulatory cardiac monitoring. Circulation. 2024;150:A4141717. doi:10.1161/circ.150.suppl_1.4141717. https://www.ahajournals.org/doi/abs/10.1161/circ.150.suppl_1.4141717 
  19. Data on file. iRhythm Technologies, 2024 
  20. Data on file. iRhythm Technologies, 2023.
  21. Data on file. iRhythm Technologies, 2022. 
  22. Based on the US market data using Zio ECG monitors.

 

The Zio™ service is a long-term continuous ambulatory cardiac monitoring service. It consists of the Zio™ monitor that collects beat-to-beat ECG data and can be worn for up to 14 days; the Zio™ ECG Utilization Service (ZEUS) System deep learned algorithm, which detects arrhythmias. The data is reviewed and curated by a team of Qualified ECG Specialists (QES) to provide the final patient report.

 

For indications for use, warnings & contraindications, visit here.

 

iRhythm, Zio, Zio monitor and ZioSuite are trademarks of iRhythm Technologies, Inc. ©2024 All rights reserved.

 

Zio™ monitor and ZEUS are CE-marked (CE2797).

 

Zio monitor, ZEUS and Zio service are currently available in Austria, Netherlands, Spain & Switzerland.

 

For further regulatory information visit here.

 

WEB0205.01